SKY-0515

PreclinicalSmall molecule

SSkyhawk Therapeutics, Inc.

SKY-0515 is one of 18 small molecule programs targeting Huntington disease. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Huntington DiseaseRecruiting

Huntington's Disease (HD)Enrolling by invitation

Huntington DiseasePreclinical

Recruiting

Huntington's Disease (HD)Preclinical

Enrolling by invitation

Competition

Competitive Landscape

19 competitors in Huntington Disease

#DrugCompanyPhaseTrials

Dojolvi

Actigall

Epidiolex

Tasigna

AAzurity Pharmaceuticals

Haldol

Minocin

Glucophage

Rilutek

AAzurity Pharmaceuticals

Approved

—9

Acetadote

AArbor Pharmaceuticals, Inc.

Risperdal

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2/3Recruiting

Huntington's Disease

NCT06873334

Q3 2029

PreclinicalRecruiting

Huntington Disease

NCT07378644

Clinical

Trials by Indication[1]

Huntington's Disease1 trial

Study of SKY-0515 for Safety, Efficacy, and Pharmacodynamics in Participants With Huntington's Disease

Recruiting·SSkyhawk Therapeutics, Inc.·Phase 2/3·NCT06873334·120 enrolled

Huntington disease1 trial

A Phase 2/3 Randomized, Double Blind, Placebo-Controlled, Dose Ranging Study to Evaluate the Pharmacodynamics, Safety and Efficacy of SKY-0515 in Participants With Huntington's Disease

Recruiting·SSkyhawk Therapeutics, Inc.·Preclinical·NCT07378644·400 enrolled

Huntington's Disease (HD)1 trial

An Open Label Extension of SKY-0515 in Participants With Huntington's Disease Who Completed a Prior SKY-0515 Treatment Study

Enrolling by invitation·SSkyhawk Therapeutics, Inc.·Preclinical·NCT07537075·500 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for SKY-0515. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SKY-0515 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SKY-0515. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Skyhawk Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: SSkyhawk Therapeutics, Inc.

SKY-0515

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q3 2029

Trials by Indication[1]

Huntington's Disease1 trial

Huntington disease1 trial

Huntington's Disease (HD)1 trial

References

Drug Info

Quick Facts

Related News